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Abstract 
Purpose: To assess the effects of prostaglandin F2α analogues travoprost on the 
biomechanical behavior of ex-vivo rabbit cornea. 
Methods: 18 Japanese white rabbits were included in the study. The left eye (treated 
group, Tr) of each rabbit was preserved for 10 days in storage medium Eusol-C solution 
with 1:10 travoprost diluent, while the contralateral eye (control group, Co) was 
preserved in a similar but travoprost-free medium. Strips of corneal tissue were 
dissected and tested under cyclic load conditions with up to 0.1 N uniaxial tension force. 
The resulting load-elongation data were used to derive the stress-strain behavior and 
the tangent modulus (Et) of the tissue. Differences in Et between the treated (Et-Tr) and 
control group (Et-Co) were assessed statistically to determine the biomechanical effects 
of travoprost on the cornea. 
Results: Central corneal thickness remained similar in the two groups before (p= 0.073) 
and after storage (p= 0.303), although it became significantly thicker in both groups 
after storage (P< 0.01). Compared with the control group, the travoprost treated corneas 
exhibited lower Et values but the differences reduced and became insignificant with 
rises in stress to which the tissue was subjected (1 - Et-Tr/Et-Co = -11.7±41.8%, p< 0.05 
at 10 kPa stress, -9.2±36.1%, p> 0.05 at 20 kPa, -7.3±35.4%, p>0.05 at 30 kPa). 
Conclusions: Significant reductions in corneal stiffness, that are associated with the 
use of travoprost, were observed experimentally under low applied stresses. This 
stiffness-reduction effect should be considered in clinical management, especially in 
primary open angle glaucoma treatment. 
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Introduction 
Glaucoma, the second leading cause of blindness worldwide 1, is a form of optic 
neuropathy associated with progressive degeneration of retinal ganglion cells and 
irreversible vision loss 2. Raised intraocular pressure (IOP) remains the most important 
risk factor, and reduction of IOP can slow the progression of optic neuropathy 3 and is 
reportedly the most effective management method for glaucoma. Pharmacologic 
therapy is the initial treatment for glaucoma, and the most commonly prescribed classes 
of topical hypotensive agents are prostaglandin analogs (PGAs), especially for primary 
open angle glaucoma (POAG) 4. Prostaglandin F2α analogues (PGF 2α) upregulates 
the activity of matrix metalloproteinase (MMP) and downregulates the tissue inhibitor 
of metalloproteinase (TIMP) 5-7, which results in remodeling of the extracellular matrix, 
increasing the space between the bundles of smooth muscle cells, allowing better 
outflow and leading to lowering of IOP. 
 
However, in addition to the effect of PGAs-induced IOP reduction, PGF 2α has been 
shown to decrease the collagen fibril density and corneal thickness 8, 9. Fibroblasts and 
extracellular matrix are the main structural components of the cornea, responsible to a 
large extent for determining corneal biomechanical properties. Collagen degradation 
caused by long-term topical prostaglandin therapy could influence corneal 
biomechanical behavior and induce reductions in corneal hysteresis (CH), corneal 
resistance factor (CRF) – both measured by the Ocular Response Analyzer, ORA) 10 – 
and the deformation amplitude (DA) provided by the Corvis ST (CVS) 11. Changes in 
corneal biomechanical properties after long-term topical prostaglandin therapy possibly 
introduces inaccuracies in IOP measurement and in other applications that require 
knowledge of corneal biomechanics such as planning of surgical procedures, 
assessment of stiffness deterioration associated with keratoconus and optimization of 
corneal cross-linking treatment 12. 
 
Corneal biomechanical metrics provided by the ORA and CVS have been widely used 
to assess the general biomechanical response of the cornea. Nevertheless, these metrics 
may be influenced by corneal shape and the intraocular pressure (IOP), and their links 
to standard mechanical properties, such as the tangent modulus of tissue (Et), have not 
been established 12-14. This study aims to address this shortfall through an experimental 
investigation of whether the usage of PGF 2α (in particular travoprost) influences the 
biomechanics of corneal tissue. 
 
Materials and methods 
2.1. Experimental animals 
Eighteen Japanese white rabbits (2-3 kg) from the Animal Breeding Unit at Wenzhou 
Medical University were included in this study. All animals were treated in agreement 
with the ARVO Statement for Use of Animals in Ophthalmic and Vision Research, and 
every effort was made to minimize suffering. This study was approved by the Animal 
Care and Ethics Committee of the University’s Eye Hospital. 
 
2.2. Experimental design 
After being euthanized by intravenous injection of high concentrations of pentobarbital 
sodium (Merok, Germany), bilateral eyes of each rabbit were immediately enucleated. 
The entire cornea, with the adjacent 3 mm wide scleral strip, was extracted from each 
ocular globe while all other ocular components were removed. The left eyes of the 18 
rabbits, which form the treated group (Tr), were placed in storage medium of Eusol-C 
solution (Alchimia S.r.l, Ponte S. Nicolo`, Italy) with 0.0004% travoprost (Travatan; 
Alcon Laboratories, Inc., Fort Worth, TX) diluent (1:10 dilution of stock solution). The 
corresponding 18 right eyes constituted the control group (Co), and were placed in the 
same medium but without travoprost. Based on other studies 15, 16, the 1/10 dilution was 
selected to take into account the relatively short duration of storage adopted in the study 
compared to the long-term exposure in clinical usage. All corneas were incubated in 
standard incubator conditions (37°C, 5% CO2) for 10 days as described in a previous 
study 17. 
 
2.3. Biomechanical Tensile Testing 
A 2-mm-wide corneoscleral strip centered on the cornea was excised from each 
specimen using two parallel surgical blades along the inferior-superior direction. The 
strips were connected to a pair of mechanical clamps, leaving a distance of 10mm in 
between. An electronic caliper (Exploit 033004, Exploit Tools Group, Yiwu, China) 
was used to measure the thickness (t) and width (w) of the strip in 5 equally-spaced 
locations along this length. Mechanical tests were conducted using a material testing 
machine (EZ-Test, Shimadzu, Kyoto, Japan) equipped with a 50 N capacity load cell at 
a room temperature of 22°C, Figure 1. The initial distance between the clamps was 
measured by a vernier caliper and recorded as Lo. The specimens were conditioned by 
four cycles of loading and unloading with 1mm/min elongation rate and 0.10N max 
load, and the behavior recorded in the fourth cycle was considered representative of 
specimens’ stable behavior 18. The order of testing paired specimens, obtained from the 
same animal, was randomized and recorded. Strips were covered with gauze soaked 
with Phosphate buffered saline (PBS, Maixin, China) to keep them moist during the test 
procedure. 
 
The load–displacement (F–△L) data obtained from the fourth cycle were used to 
calculate the stress under each load, F, as σ = $%∙', where t was the average corneal 
thickness and w the average specimen width. The related strain was obtained as ε = △L 
/ Lo. The stress-strain results were fitting to an exponential function σ = A ∙ (e+∙, −1), where A and B were constants, and the tangent modulus (Et) was calculated as	𝐸' =2324 = A ∙ B ∙ e+∙, = 𝐵 ∙ (𝜎 + 𝐴). 
 
2.6 Statistical analysis 
All analyses were performed using the PASW Statistics 20.0 (SPSS Inc., Chicago, 
USA). Comparisons of biomechanical and geometrical parameters in the two specimen 
groups were performed using the paired T-test. P values less than 0.05 were considered 
indicative of statistical significance. 
 Results 
3.1. Corneal thickness 
After 10 days of incubation in culture medium with 0.0004% travoprost diluent, the 
central corneal thickness (CCT) of the treated group increased from 369.4±22.5 µm to 
658.9±184.4 µm (p<0.01), and in control group from 363.8±19.3 µm to 602.4±208.1 
µm (p<0.01). There were no significant differences in corneal thickness between the 
two groups before storage (p= 0.073), and the difference in corneal thickness between 
the groups remained statistically non-significant (p= 0.303) after incubation. 
 
3.2 Biomechanical behavior 
There was a clear difference in the load-displacement behavior observed for the two 
specimen groups as shown in Figure 2. With material parameters A and B determined 
(Table 1), the stress-strain (σ-ε) relationships (Figure 3), and hence the tangent modulus 
(Et = dσ/dε) at any stress level can be obtained. For statistical evaluation purposes, the 
Et values were compared at 10, 20 and 30 kPa stresses, the first two of which were 
within the tissue’s nonlinear stage, while the third was within the later linear part. At 
10 kPa stress, Et was significantly lower in the treated group (Et-Tr), compared to the 
control groups (Et-Co), but this difference reduced in value and became insignificant 
under 20 and 30 kPa (Table 2). 
 
Discussion 
Topical medication is commonly used in the primary management of glaucoma. Among 
the several anti-glaucoma eye drops developed, PGF 2α are considered highly effective 
first-line agents because of their significant success in lowering IOP levels 19, that is in 
spite of reported side effects including eyelid skin darkening 20, iris pigmentation 21, 
conjunctival hyperemia 22 and ocular irritation 23. While these biological side effects 
have been considered previously 15, 24, little attention has been given to the effect of 
PGF 2α on corneal biomechanics. PGF 2α have previously been found to accelerate 
collagen degradation 25, decrease fibronectin protein content 26, stimulate collagen gel 
contraction 27 and change collagen distribution in corneal stroma 26. Since collagen 
fibrils are the main load carrying components of the cornea , these effects may lead to 
material stiffness reduction. This study, which attempted to address this point, showed 
that travoprost eye drops significantly reduced the mechanical stiffness (as measured 
by the tangent modulus, Et) of the ex-vivo rabbit cornea. 
 
Earlier studies that relied on the ORA and CVS to provide indications of the 
biomechanical effects of PGAs produced inconsistent results. While some studies 
reported increases in corneal hysteresis parameter (CH – a measure of corneal 
viscoelasticity) with PGA treatment 28-33, others reported decreases 10. Also, there was 
no agreement on the effect of PGAs on the corneal resistance factor (CRF – a measure 
of corneal stiffness) with reported increases 31, decreases 10, 33, and no significant change 
28,32. However, after adjusting for IOP, CCT and other factors, which may influence 
corneal behavior, a significant reduction in the CVS’s deformation amplitude (DA – a 
measure of corneal stiffness) was detected after PGA therapy 11. Nevertheless, since the 
biomechanical metrics provided by the ORA and CVS cannot be linked directly to the 
traditional measures of tissue stiffness (primarily Et), and could be influenced by factors 
such as IOP and CCT 12-14, the present study relied instead of the classic tensile test in 
quantifying the effect of PGAs on corneal biomechanics. 
 
The uniaxial tension test is a simple and well-accepted experimental technique for 
characterizing the mechanical behavior of tissue 34. In spite of the limitations caused by 
the initially curved form of specimens and the termination of fibrils along the specimen 
sides 35, the test method remains viable for comparative studies, such as the present 
research, where the focus is on the variation in tissue behavior due to different treatment 
regimes. All specimens exhibited clear nonlinear behavior, as indicated in a previous 
study 36, with an initial low stiffness increasing gradually until a stage of constant 
stiffness was reached at stresses slightly below 30 kPa. In order to ensure the test results 
were repeatable, three loading-unloading cycles were carried out before using the 
results of the forth cycle as representative of specimens’ stable behavior 18. The results 
showed significant decreases in Et in the treated group, by -11.7±41.8% (p< 0.05) at a 
stress of 10 kPa compared to the control group. However, these differences decreased 
and became insignificant with higher stress levels (-9.2±36.1%, p> 0.05 at 20kPa and -
7.3±35.4%, p> 0.05 at 30 kPa). 
 
The changes in tissue stiffness reported in this study may well influence the accuracy 
of IOP measurement – needed for glaucoma management 37. Most tonometry 
techniques, contact or non-contact, depend on applying a mechanical force and 
correlating corneal resistance to deformation under this force to the value of IOP. While 
simple and easy to implement, this measurement concept makes the estimation of IOP 
dependent on corneal biomechanical properties 38. With the application of PGAs 
leading to reductions in corneal stiffness, and hence underestimations of true IOP, the 
result may be an overestimation of the effect of PGAs in lowering IOP, which can have 
significant implications for glaucoma management. 
 
There was a significant thickness increase observed during the storage period – due to 
tissue swelling – which correlated with the anaerobic state and increased lacate 
concentration 39 caused by the storage medium. The increase in corneal thickness, 
which affected both treated and control groups, may have masked the thickness 
reduction effect caused by PGAs usage as reported in earlier studies 8, 9, possibly as 
PGF 2α can induce excessive production of MMPs and inhibit the production of TIMP, 
both of which lead to an accelerated matrix degradation and decrease in CCT. 
 
The present study relied on rabbit eyes due to their similarity to human eyes in 
biomechanical behavior 40, 41, and the difficulty in obtaining human donor eyes in 
sufficient numbers for research. The tests were also done ex vivo, and while concerted 
efforts were made to preserve the tissue and test it within 2 hours post-mortem, there 
may have some degradation, which can affect the results obtained. 
 
To the best of our knowledge, this is the first study to investigate the effect of PGAs 
hypotensive medications on corneal biomechanical property changes measured in 
standard biomechanical experiments. Corneal material stiffness reduced significantly 
with the use of PGF 2α (travoprost diluent, 0.0004%), causing concern over the 
accuracy of IOP measurement in patients undergoing chronic PGA therapy. This finding 
warrants caution when evaluating IOP measurements and the results of patient follow-
up. Further investigation is required to quantify the effect of the stiffness reduction 
reported herein on the IOP measurements with commonly used tonometers, and hence 
the management of glaucoma. 
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Figure Captions: 1 
Figure 1 Corneal specimen and experimental platform 2 
Figure 2 Mean load-displacement behavior in treated and control groups 3 
Figure 3 Mean stress-strain behavior of corneas in each specimen group – error bars 4 
represent standard deviation of strain values 5 
 6 
 7 
 8 
Figure1 Corneal specimen and experimental platform, A. front view of testing strip 9 
specimens after assembly, B. side view of testing strip specimens after assembly, C. 10 
material testing machine 11 
 12 
Figure 2 Mean load-displacement behavior in treated and control groups 13 
 14 
Figure 3 Mean stress-strain behavior of corneas in the treated and control groups – 15 
error bars represent the standard deviation of strain values 16 
Table Captions: 
Table 1 Mean and standard deviation of constitutive parameters A and B in two 
specimen groups 
Table 1 Mean and standard deviation of constitutive parameters A and B in the two specimen 
groups 
Group A B RMS, mm 
Treated group 0.002 ± 0.003 66.481 ± 23.706 0.0017 ± 0.0014 
Control group 0.004 ± 0.006 71.495 ± 26.946 0.0012 ± 0.0008 
 
  
Table 2 Average and standard deviation values of tangent modulus (MPa) in treated and 
control groups at three stress levels 
Stress (kPa) 
Tangent Modulus, Et (MPa) 
p Et-Tr/Et-Co, % 
Tr Co 
10 0.78 ± 0.27 1.00 ± 0.45 0.025 88.3 ± 41.8 
20 1.45 ± 0.49 1.71 ± 0.64 0.059 90.8 ± 36.1 
30 2.11 ± 0.72 2.43 ± 0.88 0.119 92.7 ± 35.4 
Tr = treated group, Co = control group; Et-Tr/Et-Co = ratio between tangent modulus in treated 
group (Et-Tr) and control group (Et-Co) 
